Literature DB >> 11036054

Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori.

D H Kwon1, J J Kim, M Lee, Y Yamaoka, M Kato, M S Osato, F A El-Zaatari, D Y Graham.   

Abstract

Tetracycline is an important component of combination therapies for Helicobacter pylori eradication. Twenty-nine tetracycline-resistant isolates requiring MICs ranging from 4 to 16 microgram/ml were isolated from Korean (22 of 460) and Japanese (7 of 105) patients. Interestingly, all of the 29 tetracycline-resistant isolates exhibited cross-resistance to metronidazole, and the cross-resistance was transferred to tetracycline-sensitive H. pylori strains.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11036054      PMCID： PMC101634          DOI： 10.1128/AAC.44.11.3203-3205.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance.

Authors:  D Y Graham; W A de Boer; G N Tytgat
Journal:  Am J Gastroenterol       Date:  1996-06       Impact factor: 10.864

Review 2.  Helicobacter pylori: the size of the problem.

Authors:  J Parsonnet
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

Review 3.  Multidrug efflux pumps of gram-negative bacteria.

Authors:  H Nikaido
Journal:  J Bacteriol       Date:  1996-10       Impact factor: 3.490

Review 4.  Tetracyclines: antibiotic action, uptake, and resistance mechanisms.

Authors:  D Schnappinger; W Hillen
Journal:  Arch Microbiol       Date:  1996-06       Impact factor: 2.552

5.  Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study.

Authors:  F Mégraud; N Lehn; T Lind; E Bayerdörffer; C O'Morain; R Spiller; P Unge; S V van Zanten; M Wrangstadh; C F Burman
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

6.  Helicobacter pylori resistance to tetracycline.

Authors:  P D Midolo; M G Korman; J D Turnidge; J R Lambert
Journal:  Lancet       Date:  1996-04-27       Impact factor: 79.321

Review 7.  Helicobacter pylori.

Authors:  J Parsonnet
Journal:  Infect Dis Clin North Am       Date:  1998-03       Impact factor: 5.982

Review 8.  Lymphoma of the gastrointestinal tract.

Authors:  M Crump; M Gospodarowicz; F A Shepherd
Journal:  Semin Oncol       Date:  1999-06       Impact factor: 4.929

Review 9.  Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution.

Authors:  M C Roberts
Journal:  FEMS Microbiol Rev       Date:  1996-10       Impact factor: 16.408

10.  Aflagellated mutants of Helicobacter pylori generated by genetic transformation of naturally competent strains using transposon shuttle mutagenesis.

Authors:  R Haas; T F Meyer; J P van Putten
Journal:  Mol Microbiol       Date:  1993-05       Impact factor: 3.501
View more
  18 in total

Review 1.  Eradication of Helicobacter pylori: a clinical update.

Authors:  Marco Romano; Antonio Cuomo
Journal:  MedGenMed       Date:  2004-02-17

2.  Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh.

Authors:  Shamsun Nahar; Asish K Mukhopadhyay; Rasel Khan; Mian Mashhud Ahmad; Simanti Datta; Santanu Chattopadhyay; Swapan Chandra Dhar; Shafiqul Alam Sarker; Lars Engstrand; Douglas E Berg; G Balakrish Nair; Motiur Rahman
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

3.  Antibiotic susceptibility of Helicobacter pylori clinical isolates: comparative evaluation of disk-diffusion and E-test methods.

Authors:  K K Mishra; S Srivastava; A Garg; A Ayyagari
Journal:  Curr Microbiol       Date:  2006-09-12       Impact factor: 2.188

4.  Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori.

Authors:  Guofei Dai; Ni Cheng; Lei Dong; Mutsumi Muramatsu; Shudong Xiao; Ming-Wei Wang; De-Xu Zhu
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline.

Authors:  Catharine A Trieber; Diane E Taylor
Journal:  J Bacteriol       Date:  2002-04       Impact factor: 3.490

6.  Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

Authors:  Kathleen R Jones; Jeong-Heon Cha; D Scott Merrell
Journal:  Curr Drug ther       Date:  2008-09-01

7.  Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci.

Authors:  Daiva Dailidiene; M Teresita Bertoli; Jolanta Miciuleviciene; Asish K Mukhopadhyay; Giedrius Dailide; Mario Alberto Pascasio; Limas Kupcinskas; Douglas E Berg
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

8.  High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin.

Authors:  Maribel Rodríguez-Torres; Rosa Salgado-Mercado; Carlos F Ríos-Bedoya; Edgardo Aponte-Rivera; Acisclo M Marxuach-Cuétara; José F Rodríguez-Orengo; Alberto Fernández-Carbia
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

9.  16S rRNA mutations that confer tetracycline resistance in Helicobacter pylori decrease drug binding in Escherichia coli ribosomes.

Authors:  Lisa Nonaka; Sean R Connell; Diane E Taylor
Journal:  J Bacteriol       Date:  2005-06       Impact factor: 3.490

10.  Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori.

Authors:  Monique M Gerrits; Marco Berning; Arnoud H M Van Vliet; Ernst J Kuipers; Johannes G Kusters
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.